Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody.
We report the first case of 90Y-conjugated monoclonal antibody (MoAb) administration for human radioimmunotherapy. Ten mCi 90Y-labeled antiidiotype (anti-Id) MoAb were administered to a patient with B-cell lymphoma whose tumor successfully imaged with 111In-labeled anti-Id MoAb. No significant toxicities were observed. More than 2 g of unlabeled anti-Id MoAb were administered while clearing the circulating IgM idiotype prior to administration of the 90Y-MoAb. Transient partial regression of disease was observed. Serial fine needle aspirations of a malignant lymph node documented in vivo anti-Id penetration into a site that did not image by radioimmunoscintigraphy. The radiosensitivity of B-cell lymphoma, the tumor specificity of anti-Id, the antitumor activity of anti-Id alone, and the safe administration of 10 mCi 90Y-labeled anti-Id MoAb in this report suggest further investigation of this radioimmunoconjugate for therapy of B-cell lymphoma is warranted.
Parker
B A
BA
University of California, San Diego Cancer Center 92103.
Vassos
A B
AB
Halpern
S E
SE
Miller
R A
RA
Hupf
H
H
Amox
D G
DG
Simoni
J L
JL
Starr
R J
RJ
Green
M R
MR
Royston
I
I
D000328:Adult; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001402:B-Lymphocytes; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D008223:Lymphoma / Q000000981:diagnostic imaging / Q000628:therapy*; D051379:Mice; D011877:Radionuclide Imaging; D015021:Yttrium Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D015021:Yttrium Radioisotopes